- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about IBB
Recent news which mentions IBB
Chart of the Week: What Sector Looks Healthiest to Advisors
November 10, 2022
From ETF Trends
‘Just so full of autocracies’: For the Freedom 100 Emerging Markets ETF, outperformance in 2022 goes beyond nixing China
November 03, 2022
From MarketWatch
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
These 4 ETFs Feature on CNBC's 'Final Trades'
October 27, 2022
From Benzinga
SBIO Rallied While Major Indexes Declined Last Week
October 04, 2022
From ETF Trends
From Benzinga
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
September 27, 2022
From InvestorPlace
SBIO Outpaced XBI, IBB in Volatile Last Week
September 21, 2022
From ETF Trends
From MarketWatch
The Best Biotech Stock to Own in September
September 06, 2022
From Motley Fool
SBIO Was ALPS’ Top Performing ETF in August
September 01, 2022
From ETF Trends
From Benzinga
Biotech ETFs Are on the Mend
August 19, 2022
From ETF Trends
SBIO Rallies on M&A Announcements
August 10, 2022
From ETF Trends
From Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
From Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
From Benzinga
From Benzinga
From Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
From Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 01, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Market Predictions 2022: When Will Stocks Go Back Up?
July 22, 2022
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.